The EU Clinical Trials Directive has been heavily criticised for being bureaucratic, confusing, and leading to a decline in the number of trials conducted in Europe. Although new proposals for regulation are much better, Peter Gøtzsche argues improvements are still needed for patient safety, rational use of drugs, and research planning.
↧